Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05581004 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Colorectal Cancer and Melanoma, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT05581004: Recruiting Phase 1 study of Colorectal Cancer and Melanoma, sponsored by Genentech.
NCT05581004 is a Phase 1 study of Colorectal Cancer and Melanoma that is actively recruiting participants, run by Genentech. The registered enrollment target is 450 participants, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05581004, a Phase 1 study of Colorectal Cancer and Melanoma, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Atezolizumab
- DRUG RO7502175
Study Locations (20)
Other
- UZ Antwerpen - Edegem
- CHU de Liège - Herstal
- GasthuisZusters Antwerpen - Wilrijk
Tennessee
- The West Clinic - Memphis (Union Ave) - Germantown
- SCRI Oncology Partners - Nashville
Ontario
- Ottawa Hospital Regional Cancer Centre - Ottawa
- Princess Margaret Cancer Centre - Toronto
California
- Stanford University - San Francisco
Colorado
- University Of Colorado - Aurora
Florida
- Florida Cancer Specialists - Sarasota - Sarasota
Georgia
- Winship Cancer Institute - Atlanta
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 1 |
What NCT05581004 shows while recruiting
NCT05581004 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (71% lower).
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05581004 names 20 study sites across 16 states, led by Other, Tennessee, Ontario.
Frequently Asked Questions
What is clinical trial NCT05581004 about?
NCT05581004 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors". This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including...
What is the current status of trial NCT05581004?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 450 participants. The study started on 2022-10-20. Estimated completion is 2027-02-28.
What conditions does trial NCT05581004 study?
This clinical trial studies the following conditions: Colorectal Cancer, Melanoma, Gastric Cancer, Cervical Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT05581004?
The interventions under investigation include: Pembrolizumab (DRUG), Atezolizumab (DRUG), RO7502175 (DRUG).
Who is sponsoring clinical trial NCT05581004?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05581004 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05581004's enrollment target sits among peer trials
450 87th of 381 higher than 295 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI